Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi
View: Text | PDF
Research Article Angiogenesis

VEGFA165 gene therapy ameliorates blood-labyrinth barrier breakdown and hearing loss

  • Text
  • PDF
Abstract

Millions of people are affected by hearing loss. Hearing loss is frequently caused by noise or aging and often associated with loss of pericytes. Pericytes populate the small vessels in the adult cochlea. However, their role in different types of hearing loss is largely unknown. Using an inducible and conditional pericyte depletion mouse model and noise-exposed mouse model, we show that loss of pericytes leads to marked changes in vascular structure, in turn leading to vascular degeneration and hearing loss. In vitro, using advanced tissue explants from pericyte fluorescence reporter models combined with exogenous donor pericytes, we show that pericytes, signaled by VEGF isoform A165 (VEGFA165), vigorously drive new vessel growth in both adult and neonatal mouse inner ear tissue. In vivo, the delivery of an adeno-associated virus serotype 1–mediated (AAV1–mediated) VEGFA165 viral vector to pericyte-depleted or noise-exposed animals prevented and regenerated lost pericytes, improved blood supply, and attenuated hearing loss. These studies provide the first clear-cut evidence that pericytes are critical for vascular regeneration, vascular stability, and hearing in adults. The restoration of vascular function in the damaged cochlea, including in noise-exposed animals, suggests that VEGFA165 gene therapy could be a new strategy for ameliorating vascular associated hearing disorders.

Authors

Jinhui Zhang, Zhiqiang Hou, Xiaohan Wang, Han Jiang, Lingling Neng, Yunpei Zhang, Qing Yu, George Burwood, Junha Song, Manfred Auer, Anders Fridberger, Michael Hoa, Xiaorui Shi

×

Figure 6

VEGFA165 gene therapy enhances pericyte survival, promotes pericyte regeneration, and attenuates vascular damage.

Options: View larger image (or click on image) Download as PowerPoint
VEGFA165 gene therapy enhances pericyte survival, promotes pericyte rege...
(A and B) Time points of gene delivery and related measurements. (C and D) VEGFA165 mRNA and protein are significantly increased in the AAV1-VEGFA165 gene–treated cochleae compared with the control AAV1-treated cochleae (VEGFA165 mRNA: n = 3 for each group; VEGFA165 protein: n = 6 for each group; and **P < 0.01 by Student’s t test). (E) The pericyte population is higher in the AAV1-VEGFA165 gene–treated group (n = 7) compared with the control AAV1-treated group (n = 4, ****P < 0.0001 by Student’s t test). (F) Increased EdU+ cells in the VEGFA165 gene–treated group (n = 7) compared with the control AAV1 group (n = 4, *P < 0.05, and **P < 0.01 by Student’s t test). (G) Decreased vascular density is attenuated by AAV1-VEGFA165 gene treatment (n = 7) but not by control AAV1 treatment (n = 4, ***P < 0.001 by Student’s t test). (H and I) Confocal images show EdU+ pericytes, endothelial cells, and an unidentified cell type in the stria of control AAV1 (H) and AAV1-VEGFA165 groups (l). (J) Zoomed-in images highlight different types of EdU+ cells in the stria of an AAV1-VEGFA165–treated animal. (K) Blood flow volume in the AAV1-VEGFA165–treated group is significantly greater than in the control AAV1 group (n = 3, ****P < 0.0001 by Student’s t test). (L) Vascular leakage is markedly attenuated in the AAV1-VEGFA165–treated group relative to the control AAV1 group (n = 3 for each group, **P < 0.01 by Student’s t test). (M and N) IVM images from control AAV1 and AAV1-VEGFA165 groups (white arrows, leaking sites). Data are presented as a mean ± SEM. Scale bars: 50 μm (H, I), 10 μm (J), 100 μm (M, N). PC, pericyte; EC, endothelial cell.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts